New Concepts in Molecularly Targeted Radiation in Prostate Cancerwith Dr. Sartor

12 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
A. Oliver Sartor, MD, Mayo Clinic, Rochester, Minnesota, discusses innovative approaches in molecularly targeted radiation for prostate cancer. In this 13-minute presentation, Dr. Sartor outlines the concept of theranostics, which combines imaging and therapy using radiopharmaceuticals to detect and treat prostate cancer.

Dr. Sartor highlights PSMA as a proven target and the use of Lutetium-177 for treating PSMA-positive metastatic castration-resistant prostate cancer. He introduces key clinical trials, such as PSMAfore, SPLASH, and ECLIPSE, which evaluate Lutetium-177 in earlier treatment stages. He also discusses the PSMAddition trial, which explores its role in metastatic castration-sensitive prostate cancer.

Sartor highlights promising strategies combining radiopharmaceuticals with DNA repair inhibitors like PARP inhibitors and emerging data on alpha emitters like Actinium-225 for enhanced tumor control. He stresses the potential for combining isotopes with immunotherapy and other agents to improve outcomes. Dr. Sartor emphasizes the need to expand molecular radiation therapy to additional cancer types and highlights future directions for more precise, targeted, and effective treatment strategies.

Don't forget to join the GRU Community: https://grandroundsinurology.com/register/
Follow us on Twitter/X: https://x.com/GRUrology
And like and subscribe to us here on YouTube!
Categoria
Oncology
Commenta per primo questo video.

Prossimo